Fondaparinux monitoring in a patient with heparin-induced thrombocytopenia on hemodialysis.
Srp Arh Celok Lek
; 144(11-12): 654-6, 2016.
Article
em En
| MEDLINE
| ID: mdl-29659233
ABSTRACT
Introduction:
Heparin-induced thrombocytopenia associated to hemodialysis is rare. In case when citrate dialysis and/or non-heparin anticoagulants are not available, only possible medication to use for anticoagulation during hemodialysis is fondaparinux. However, laboratory monitoring of fondaparinux based on anti-Xa activity in dialysis patients has not been sufficiently documented yet. Case Outline We created a local anti-factor Xa assay for measuring fondaparinux plasma concentration and efficacy in a patient with heparin-induced thrombocytopenia during hemodialysis. Fondaparinux given subcutaneously increases risk of adverse events due to its extended release and prolonged maintenance of toxic levels. When used intravenously fondaparinux remains safe, with reached steady-state level within dialysis and low risk of toxicity afterwards.Conclusion:
Fondaparinux may be used as an alternative anticoagulant medication during hemodialysis in patients who develop heparin-induced thrombocytopenia. Adequate dose must be adjusted to patients' dry weight (0.03 mg/kg intravenously) and fondaparinux anti-coagulation monitoring must be provided.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Polissacarídeos
/
Diálise Renal
/
Monitoramento de Medicamentos
/
Inibidores do Fator Xa
Limite:
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article